RECEIVED
CENTRAL FAX CENTER
NOV 2 8 2006

**Listing of claims**

1-24 **(Cancelled).**

25. **(New)** A method of producing a liquid spray composition for administration of a bioactive material to the nasal cavity consisting essentially of:

a) a pharmacologically acceptable non aqueous liquid carrier selected from the group consisting of diglycerides, triglycerides and mixtures thereof in which said bioactive material is directly insoluble,

b) a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier,

c) a pharmacologically acceptable water soluble glycol soluble in said ester, comprising from about 1 to about 5 wt.% of the total composition.

d) a pharmacologically acceptable water soluble bio-active material soluble in said glycol but directly insoluble in said carrier said spray being non-aqueous tasteless, odorless,

which consists essentially of the sequential steps of dissolving the bio-active material of (d) in a glycol of (c), dissolving said solution of (d) in (c) in an ester of (b) and dissolving said solution of {(d) in (c) in (b)} in a carrier of (a).

26. **(New)** The method of claim 25 wherein the carrier is selected from the group consisting of a medium chain diglyceride, a medium chain triglyceride and mixtures of said glycerides.

27. **(New)** The method of claim 26 wherein the carrier is selected from the group consisting of a medium chain ethylene diglyceride, medium chain propylene diglyceride, a medium chain propylene triglyceride and mixtures of said glycerides,

28. **(New)** The method of claim 27 wherein the glyceride moieties are selected from the group consisting of caprylic and caproic glycerides.

29. **(New)** The composition produced by the method of claim 1 comprising
a) from about 50-about 90 wt.% of the carrier,
b) from about 10-about 40 wt% of the water insoluble ester,
c) from about 1-about 5 wt.% of the water soluble glycol ,
d) from about 0.01-about 2 wt.% of the bio-active material.

30. **(New)** The composition of claim 29 comprising
a) from about 60 about 90 wt.% of the carrier,
b) from about 10 about 20 wt% of the water insoluble ester,
c) from about 1 to about 3 wt.% of the water soluble glycol,
d) from about 0.01 to about 2 wt.% of the bio-active material.

31. **(New)** The composition of claim 30 wherein the glycol is a $C_3$ to $C_8$ glycol.

32. **(New)** The composition of claim 31 wherein the glycol is selected from the group consisting of polyethylene glycol and propylene glycol.

33. **(New)** The composition of claim 29 wherein the ester is a lactate ester.

34. **(New)** The composition of claim 33 wherein the lactate ester is a $C_{12}$ - $C_{15}$ alkyl lactate

35. **(New)** The composition of claim 34 wherein the alkyl group is selected from the group consisting of cetyl, lauryl, isostearyl and myristyl and mixtures thereof.

36. **(New)** The composition of claim 29 wherein the bio-active material is selected from the group consisting of decongestants, antihistamines, antitussives, anticholinergics, steroids, antibiotics, analgesics, antispasmotics, brochodilators, vitamins, hormones, antihypertensives and antimicrobials.

37. **(New)** The composition of claim 29 wherein the bio-active material is a decongestant.

38. **(New)** The composition of claim 37 wherein the bio-active material is selected from the group consisting of oxymetazoline, xylometazoline, naphazoline, phenylephrine, ephedrine in water soluble form.

39. **(New)** The composition of claim 38 wherein the bio-active material is in the form of a pharmacologically acceptable salt.

40. **(New)** A method of administering a bio-active material to a subject in need of same which consists essentially of spraying a pharmacologically effective amount of a composition of claim 29 into the nasal cavity of said subject.

41. **(New)** The method of claim 40, wherein the bio-active material is selected from the group consisting of decongestants, antihistamines, antitussives, anticholinergics, steroids, analgesics, antibiotics, antispasmotics, brochodilators, vitamins, hormones, antihypertensives and antimicrobials.

42. **(New)** The method of claim 41, wherein the bio-active material is a decongestant.

43. **(New)** The method of claim 42, wherein the bio-active material is selected from the group consisting of oxymetazoline, xylometazoline, naphazoline, phenylephrine, ephedrine in water soluble form.